Overview
| Founded | April 16, 1913 |
|---|---|
| Incorporated | April 28, 1945 |
| Paid-In Capital | ¥7.2 billion; listed on the First Section of the Tokyo Stock Exchange |
| Employees | 1,558(Consolidated)※As of March 2021 |
| Head Office | 1-1 Ichigayahonmuracho, Shinjuku-ku, Tokyo 162-0845, Japan |
| Tel | +81-3-3358-7211 |
| Fax | +81-3-3358-7887 |
Members of the Board
| Representative Director, President | Naoyuki Mochida |
|---|---|
| Representative Director, Senior Executive Vice President | Chu Sakata |
| Member of the Board, Senior Executive Managing Officer | Keiichi Sagisaka Junichi Sakaki, Ph.D. |
| Member of the Board, Executive Managing Officer | Kiyoshi Mizuguchi, Ph.D. |
| Member of the Board, Executive Officer | Yutaka Kawakami, Ph.D. Yoshiharu Hashimoto |
| Outside Director | Tomoo Kugisawa Hirokuni Sogawa Nana Otsuki |
Audit & Supervisory Board Members
| Full-Time Audit & Supervisory Board Member | Ichiro Takahashi Kazuhiro Miyaji |
|---|---|
| Outside Audit & Supervisory Board Member | Kyosuke Wagai Akiko Suzuki Yoshifumi Miyata |
Executive Officers
| Executive Officer |
Masaaki Naotsuka Tomokazu Matsusue Hitoshi Mizuno Taiji Hayano Kazunari Nakao Kenji Miyajima Takeshi Mochida Reiko Nakano Yoshitaka Hosaka, Ph.D. Masayoshi Takeda Junichi Makino |
|---|
Consolidated Financial Highlights
| Millions of Yen | |||
|---|---|---|---|
| 2022 (forecast) |
2021 | 2020 | |
| Net sales | 101,500 | 102,995 | 101,799 |
| Operating income | 8,000 | 12,003 | 8,807 |
| Income before income taxes and minority interests |
– | 11,900 | 6,273 |
| Income taxes | – | 3,312*1 | 1,675*1 |
| Net income | 6,000 | 8,587 | 4,598 |
| Total assets | – | 161,791 | 157,488 |
| R&D expenditures | 13,500 | 10,849 | 11,884 |
| Capital expenditures | 1,600 | 1,335 | 1,889 |
| Yen | |||
| Net income per share | 156.8 | 222.3 | 117.6 |
| Cash dividends per share | 80.0 | 90.0 | 80.0 |
- *1 As a result of tax effect accounting, corporate tax, resident tax and business tax (total \3,144 million), income taxes-deferred(\168 million)is included.
- *2 As a result of tax effect accounting, corporate tax, resident tax and business tax (total \2,349 million), income taxes-deferred(-\674 million)is included.
Sales of Main Products
| Billions of Yen | ||||
|---|---|---|---|---|
| Products | 2022 (forecast) |
2021 | 2020 | |
| Lexapro® | Antidepressant | 14.7 | 15.5 | 16.5 |
| Lialda® | Treatment of ulcerative colitis | 11.2 | 10.9 | 9.0 |
| Epadel | Drug for hyperlipidemia and arteriosclerosis obliterans | 8.3 | 10.1 | 12.1 |
| Goofice® | Treatment for chronic constipation | 6.6 | 4.9 | 3.7 |
| Tramcet® | Analgesic for chronic pain and pain after tooth extraction | 3.1 | 4.2 | 7.1 |
| Atelec® | Calcium channel blocker with a long-acting hypotensive effect | 2.7 | 3.9 | 4.5 |
| Movicol® | Treatment for chronic constipation | 3.8 | 3.5 | 1.8 |
| Doxil® | Anticancer agent | 2.6 | 3.0 | 2.8 |
| Dinagest | Therapeutic agent for endometriosis, adenomyosis and dysmenorrhea | 2.0 | 2.2 | 1.6 |
| Treprost® | Treatment for pulmonary arterial hypertension | 1.7 | 1.6 | 1.9 |
| Heparin Sodium MOCHIDA | Anticoagulant agent | 1.3 | 1.3 | 1.4 |
| Beselna | Therapeutic agent for condyloma acuminatum and actinic keratosis | 1.0 | 1.0 | 1.0 |
| Florid® | Antimycotic drug | 1.0 | 0.9 | 1.0 |
| Urece | Gout and hyperuricemia | 2.2 | 0.2 | – |
| Generic drugs | 24.9 | 25.6 | 23.3 | |
| Skin Care Products | 5.9 | 5.7 | 5.3 | |